CHRNA10
MOLECULAR TARGETcholinergic receptor nicotinic alpha 10 subunit
CHRNA10 (cholinergic receptor nicotinic alpha 10 subunit) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CHRNA10
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Nicotine Nicotine is highly toxic alkaloid. It is | 3.18 | 23 |
| 2 | mg624 | 1.61 | 4 |
| 3 | Dimethylphenylpiperazinium Iodide | 1.10 | 2 |
| 4 | Lobeline | 1.10 | 2 |
| 5 | Arecoline | 0.69 | 1 |
| 6 | Mecamylamine | 0.69 | 1 |
| 7 | Muscarine | 0.69 | 1 |
| 8 | Pioglitazone | 0.69 | 1 |
| 9 | Strychnine | 0.69 | 1 |
About CHRNA10 as a Drug Target
CHRNA10 (cholinergic receptor nicotinic alpha 10 subunit) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented CHRNA10 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CHRNA10 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.